1. Home
  2. TLSA vs LEE Comparison

TLSA vs LEE Comparison

Compare TLSA & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$1.10

Market Cap

155.3M

Sector

Health Care

ML Signal

N/A

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

N/A

Current Price

$9.88

Market Cap

209.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
LEE
Founded
2013
1890
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
155.3M
209.0M
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
TLSA
LEE
Price
$1.10
$9.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
284.0K
69.5K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$543,955,000.00
Revenue This Year
N/A
$5.48
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$3.34
52 Week High
$2.60
$11.88

Technical Indicators

Market Signals
Indicator
TLSA
LEE
Relative Strength Index (RSI) 34.60 50.03
Support Level N/A $7.95
Resistance Level $1.44 $11.88
Average True Range (ATR) 0.11 0.85
MACD -0.03 -0.13
Stochastic Oscillator 13.33 11.44

Price Performance

Historical Comparison
TLSA
LEE

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: